The TNT and CBCSG006 trials examining the benefit of the first-line platinum agents in patients with metastatic TNBC have included those with BRCA1/2 GPV [71,80,81]; however, no randomized controlled trials have investigated the efficacy of platinum-based chemotherapy in patients with BRCA1/2-related advanced BC. This evidence concerns the gene BRCA1 and breast cancer.